TSLPR: A new CAR in the showroom for B-ALL

Blood

Volumn 126, Issue 5, 2015, Pages 567-569

  Davies, David Marc ^a   Maher, John ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BARNET HOSPITAL   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR LIKE FACTOR 2; HLA F ANTIGEN; JANUS KINASE 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; THYMIC STROMAL LYMPHOPOIETIN; THYMIC STROMAL LYMPHOPOIETIN RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; APLASIA; B LYMPHOCYTE DIFFERENTIATION; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOKINE RELEASE SYNDROME; DENDRITIC CELL; GENE OVEREXPRESSION; HUMAN; IMMUNE EVASION; IMMUNOGLOBULIN DEFICIENCY; IN VITRO STUDY; LEUKEMIA REMISSION; NONHUMAN; NOTE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; T LYMPHOCYTE;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CYTOKINE; T-LYMPHOCYTES;

EID: 84940192707     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-650812     Document Type: Note

References (10)

1. Qin H, Cho M, Haso W, et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015;126(5):629-639.
2. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826.
3. Maher J. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr Gene Ther. 2014;14(1):35-43.
4. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
5. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-2698.
6. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-1246.
7. Jia M, Wang ZJ, Zhao HZ, et al. Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis. World J Pediatr. 2015;11(2):126-133.
8. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 2012;120(4):833-842.
9. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
10. van der Stegen SJ, Davies DM, Wilkie S, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J Immunol. 2013;191(9):4589-4598.